+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Eptacog Alfa"

Coagulation Factor VII Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Coagulation Factor VII Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 49 Pages
  • Global
From
  • 1 Results (Page 1 of 1)
Loading Indicator

Eptacog Alfa is a hematological drug used to treat hemophilia A, a genetic disorder that impairs the body's ability to form blood clots. It is a recombinant form of Factor VIII, a protein that helps the body form clots. Eptacog Alfa is used to replace the missing Factor VIII in patients with hemophilia A, allowing them to form clots and stop bleeding. It is administered intravenously or subcutaneously, and is available in both a short-acting and a long-acting form. Eptacog Alfa is a relatively new drug, and the market is still developing. It is currently approved in the United States, Europe, and Japan, and is being studied in other countries. The drug is used to treat both adults and children with hemophilia A, and is seen as a safe and effective treatment option. Companies in the Eptacog Alfa market include Novo Nordisk, Pfizer, and Shire. Show Less Read more